Cole-Parmer Instrument Company, LLC (“Cole-Parmer”), portfolio company of GTCR LLC (“GTCR”) has acquired ZeptoMetrix Corporation (“ZeptoMetrix”). ZeptoMetrix, founded in 1999, is a life sciences developer and manufacturer of quality control standards and verification panels used in molecular diagnostic testing for infectious diseases. These products are used regularly by clinical testing labs to verify that molecular diagnostic instruments are performing and accurately detecting the presence of specific genetic material within a patient sample. The ZeptoMetrix product portfolio is focused on infectious disease, including gastrointestinal, women’s health, hospital-acquired infections, and respiratory, including the flu, RSV, and Covid, among others.

Cole-Parmer Instrument Company, LLC, a portfolio company of GTCR, is a leading global manufacturer of proprietary products for fluidics, critical research and process equipment and specialty chemicals for life sciences, environmental sampling and analysis, analytics and essential lab supplies. The acquisition of ZeptoMetrix expands CP’s quality controls and reference standards portfolio and further establishes CP as a leading manufacturer of specialty chemistries and reagents for life sciences research and diagnostic testing.

EC M&A provided M&A advice to GTCR and Cole-Parmer on this transaction.